JP7039582B2 - 活性化可能な抗ｃｔｌａ－４抗体およびその使用 - Google Patents

活性化可能な抗ｃｔｌａ－４抗体およびその使用 Download PDF

Info

Publication number
JP7039582B2
JP7039582B2 JP2019523779A JP2019523779A JP7039582B2 JP 7039582 B2 JP7039582 B2 JP 7039582B2 JP 2019523779 A JP2019523779 A JP 2019523779A JP 2019523779 A JP2019523779 A JP 2019523779A JP 7039582 B2 JP7039582 B2 JP 7039582B2
Authority
JP
Japan
Prior art keywords
antibody
seq
ctla
cancer
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500016A5 (enExample
JP2020500016A (ja
Inventor
キンバリー・アン・ティプトン
ジェイムズ・ウィリアム・ウエスト
シュリカント・デシュパンデ
ジョン・ジェイ・エンゲルハート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020500016A publication Critical patent/JP2020500016A/ja
Publication of JP2020500016A5 publication Critical patent/JP2020500016A5/ja
Priority to JP2022036450A priority Critical patent/JP7472183B2/ja
Application granted granted Critical
Publication of JP7039582B2 publication Critical patent/JP7039582B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
JP2019523779A 2016-11-03 2017-11-02 活性化可能な抗ｃｔｌａ－４抗体およびその使用 Active JP7039582B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022036450A JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417212P 2016-11-03 2016-11-03
US62/417,212 2016-11-03
PCT/US2017/059740 WO2018085555A1 (en) 2016-11-03 2017-11-02 Activatable anti-ctla-4 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022036450A Division JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2020500016A JP2020500016A (ja) 2020-01-09
JP2020500016A5 JP2020500016A5 (enExample) 2020-12-10
JP7039582B2 true JP7039582B2 (ja) 2022-03-22

Family

ID=61132883

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523779A Active JP7039582B2 (ja) 2016-11-03 2017-11-02 活性化可能な抗ｃｔｌａ－４抗体およびその使用
JP2022036450A Active JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022036450A Active JP7472183B2 (ja) 2016-11-03 2022-03-09 活性化可能な抗ｃｔｌａ－４抗体およびその使用

Country Status (19)

Country Link
US (2) US11117968B2 (enExample)
EP (1) EP3535300B1 (enExample)
JP (2) JP7039582B2 (enExample)
KR (2) KR102814027B1 (enExample)
CN (1) CN110072890B (enExample)
AR (1) AR110678A1 (enExample)
AU (1) AU2017355446A1 (enExample)
BR (1) BR112019008223A2 (enExample)
CA (1) CA3042679A1 (enExample)
CL (1) CL2019001226A1 (enExample)
CO (1) CO2019004469A2 (enExample)
EA (1) EA201990875A1 (enExample)
IL (1) IL265625A (enExample)
MX (1) MX2019004775A (enExample)
MY (1) MY200695A (enExample)
PE (1) PE20191131A1 (enExample)
SG (1) SG11201902857SA (enExample)
TW (2) TW202334213A (enExample)
WO (1) WO2018085555A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048329A2 (en) 2013-09-25 2015-04-02 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
IL270562B (en) 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Matriptase and u-plasminogen activator polypeptide substrates and other cleanable moieties, compositions comprising same and uses thereof
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
PE20191131A1 (es) 2016-11-03 2019-09-02 Bristol Myers Squibb Co Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos
CA3041279A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
CA3060618A1 (en) 2017-05-19 2018-11-22 Wuxi Biologics (Shanghai) Co. Ltd. Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
KR102771546B1 (ko) 2017-11-08 2025-02-21 야페이 상하이 바이오로지 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 생체분자의 컨쥬게이트 및 이의 용도
EP3719036A4 (en) 2017-11-28 2021-09-08 Chugai Seiyaku Kabushiki Kaisha LIGAND BINDING MOLECULE HAVING ADJUSTABLE LIGAND BINDING ACTIVITY
TW201936208A (zh) * 2017-11-28 2019-09-16 日商中外製藥股份有限公司 含有抗原結合域及運輸部分之多胜肽
EP3769309A1 (en) 2018-03-20 2021-01-27 Cytomx Therapeutics Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
IL322964A (en) 2018-05-14 2025-10-01 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of using them
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
CA3122773A1 (en) 2018-12-26 2020-07-02 Xilio Development, Inc. Anti-ctla4 antibodies and methods of use thereof
JP7581225B2 (ja) 2019-03-13 2024-11-12 メルク・シャープ・アンド・ドーム・エルエルシー Ｃｔｌａ－４遮断剤とｐｄ－１遮断剤とを含む抗癌併用療法
JP7720785B2 (ja) 2019-04-18 2025-08-08 ブリストル－マイヤーズ スクイブ カンパニー 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
CA3137512A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
CN110498856B (zh) * 2019-09-17 2020-08-11 浙江玉安康瑞生物科技有限公司 一种ctla-4单克隆抗体5h7及其用于抗肿瘤的用途
CA3160479A1 (en) 2019-11-08 2021-05-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
CA3158532A1 (en) 2019-12-19 2021-06-24 Susan Wee Combinations of dgk inhibitors and checkpoint antagonists
CA3165414A1 (en) * 2020-01-17 2021-07-22 Aetio Biotherapy, Inc. Pro-antibody that reduces off-target toxicity
CA3172641A1 (en) * 2020-04-01 2021-10-07 Xilio Development, Inc. Masked il-12 cytokines and their cleavage products
US12428470B2 (en) 2020-04-09 2025-09-30 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
AR122043A1 (es) 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
CN115803343A (zh) * 2020-05-26 2023-03-14 百奥泰生物制药股份有限公司 多特异性抗体及其应用
EP4631977A3 (en) 2020-08-11 2025-12-10 Janux Therapeutics, Inc. Cleavable linker compositions and methods
US11555078B2 (en) 2020-12-09 2023-01-17 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens
AU2022230384A1 (en) * 2021-03-01 2023-09-07 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
WO2022271544A1 (en) 2021-06-21 2022-12-29 Bristol-Myers Squibb Company Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
EP4496816A1 (en) 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
EP4499685A1 (en) 2022-03-25 2025-02-05 CytomX Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
US20250230239A1 (en) 2022-04-01 2025-07-17 Cytomx Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
EP4504257A1 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
EP4565690A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
AR130077A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Substratos escindibles por proteasas, y métodos de uso de los mismos
EP4565332A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
WO2024030845A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
AR130076A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
WO2024031032A1 (en) 2022-08-05 2024-02-08 Bristol-Myers Squibb Company Anti-ctla-4 antibodies for treatment of kras mutant cancers
EP4582453A1 (en) * 2022-09-02 2025-07-09 Cichlid Inc. Anti-ctla-4 monoclonal antibody and use thereof
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CN120936384A (zh) 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
CN120958015A (zh) 2023-04-12 2025-11-14 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536370A (ja) 2007-08-22 2010-12-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
JP2012514982A (ja) 2009-01-12 2012-07-05 サイトムエックス セラピューティクス，エルエルシー 改変した抗体組成物、それを作製および使用する方法
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
JP2016520614A (ja) 2013-05-28 2016-07-14 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP0669836B1 (en) 1992-11-13 1996-07-03 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
HU228477B1 (en) 1999-08-23 2013-03-28 Dana Farber Cancer Inst Inc Pd-1, a receptor for b7-4, and uses therefor
CA2589418A1 (en) * 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
ES2368387T5 (es) 2000-10-09 2019-03-07 Cytomx Therapeutics Inc Anticuerpos terapéuticos y que inducen tolerancia
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2598454C (en) 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
PL1907424T3 (pl) 2005-07-01 2015-12-31 Squibb & Sons Llc Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1)
EP1919931A4 (en) 2005-08-31 2010-01-20 Univ California CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF
US20090175886A1 (en) 2006-01-17 2009-07-09 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US20090220529A1 (en) 2006-03-10 2009-09-03 Diatos, S.A. Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker
JP2010507394A (ja) 2006-10-24 2010-03-11 トルービオン ファーマスーティカルズ インコーポレイテッド 改良免疫糖タンパク質のための物質および方法
US8354509B2 (en) 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
RU2017132160A (ru) 2008-12-09 2019-02-08 Дженентек, Инк. Антитела к pd-l1 и их применение для усиления функции t-клеток
RU2706200C2 (ru) 2009-11-24 2019-11-14 Медиммьюн Лимитед Специфические связывающие агенты против в7-н1
SG191955A1 (en) * 2011-02-15 2013-08-30 Immunogen Inc Cytotoxic benzodiazepine derivatives
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CN103987405B (zh) 2011-11-28 2017-03-29 默克专利股份公司 抗pd‑l1抗体及其用途
CA2871458C (en) * 2012-04-27 2020-06-23 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
IL318221A (en) 2012-05-15 2025-03-01 Bristol Myers Squibb Co Cancer immunotherapy by disrupting PD–1/PD–L1 signaling
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
AU2013278075B2 (en) 2012-06-22 2018-05-17 Cytomx Therapeutics, Inc. Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof
PT2925350T (pt) * 2012-12-03 2019-03-25 Bristol Myers Squibb Co Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
EP3004169B1 (en) 2013-05-31 2023-03-22 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
EP3044234B9 (en) 2013-09-13 2020-08-26 BeiGene Switzerland GmbH Anti-pd1 antibodies and their use as therapeutics and diagnostics
JP6343011B2 (ja) * 2013-10-07 2018-06-13 プレステージ バイオファーマ プライベート リミテッド 抗体発現用バイシストロニック発現ベクター及びそれを用いた抗体の生産方法
MX370449B (es) 2013-12-12 2019-12-13 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este.
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US10414814B2 (en) 2014-07-03 2019-09-17 City Of Hope Tumor-selective CTLA-4 antagonists
ES2881484T3 (es) 2014-12-22 2021-11-29 Pd 1 Acquisition Group Llc Anticuerpos anti-PD-1
ES2789351T3 (es) 2015-01-13 2020-10-26 Hope City Máscaras de enlace peptídico de proteínas de unión a CTLA4
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AU2016305697B2 (en) 2015-08-11 2023-02-02 WuXi Biologics Ireland Limited Novel anti-PD-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CA2993432A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN108697776A (zh) 2016-01-11 2018-10-23 阿尔莫生物科技股份有限公司 在产生抗原特异性cd8+t细胞中的白介素-10及其使用方法
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
PE20191131A1 (es) 2016-11-03 2019-09-02 Bristol Myers Squibb Co Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos
US11939385B2 (en) 2017-05-16 2024-03-26 ALX Oncology Inc. Activatable antibodies and methods of use thereof
EP3668545A2 (en) 2017-08-16 2020-06-24 Bristol-Myers Squibb Company Prodruggable antibodies, prodrugs thereof, and methods of use and making

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536370A (ja) 2007-08-22 2010-12-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
JP2012514982A (ja) 2009-01-12 2012-07-05 サイトムエックス セラピューティクス，エルエルシー 改変した抗体組成物、それを作製および使用する方法
JP2016520614A (ja) 2013-05-28 2016-07-14 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ タンパク質薬物の不活性化のための抗体ロッカー
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Also Published As

Publication number Publication date
CN110072890A (zh) 2019-07-30
TW201819412A (zh) 2018-06-01
CL2019001226A1 (es) 2019-09-13
JP7472183B2 (ja) 2024-04-22
EP3535300B1 (en) 2025-10-22
KR20190072626A (ko) 2019-06-25
TW202334213A (zh) 2023-09-01
KR20230141941A (ko) 2023-10-10
US20190359714A1 (en) 2019-11-28
CN110072890B (zh) 2022-11-29
EA201990875A1 (ru) 2019-09-30
AU2017355446A1 (en) 2019-05-02
IL265625A (en) 2019-05-30
US20220089734A1 (en) 2022-03-24
EP3535300A1 (en) 2019-09-11
TWI784983B (zh) 2022-12-01
WO2018085555A1 (en) 2018-05-11
KR102584340B1 (ko) 2023-10-10
WO2018085555A8 (en) 2018-05-31
US12441799B2 (en) 2025-10-14
SG11201902857SA (en) 2019-05-30
US11117968B2 (en) 2021-09-14
MX2019004775A (es) 2019-08-05
JP2020500016A (ja) 2020-01-09
CO2019004469A2 (es) 2019-05-10
PE20191131A1 (es) 2019-09-02
CA3042679A1 (en) 2018-05-11
AR110678A1 (es) 2019-04-24
BR112019008223A2 (pt) 2019-07-16
KR102814027B1 (ko) 2025-05-27
JP2022091800A (ja) 2022-06-21
MY200695A (en) 2024-01-11

Similar Documents

Publication Publication Date Title
JP7472183B2 (ja) 活性化可能な抗ｃｔｌａ－４抗体およびその使用
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
JP7351845B2 (ja) Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
EP3353212B1 (en) Optimized anti-cd3 bispecific antibodies and uses thereof
US20220048996A1 (en) Antibody molecules that bind cd137 and ox40
CN114874331A (zh) 治疗性抗体和它们的用途
US20250043003A1 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
JP2022529939A (ja) 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
WO2015188047A1 (en) ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
JP2024539650A (ja) 活性化可能なポリペプチド複合体
KR20240111823A (ko) 항-cd47 항체 및 이의 사용 방법
TW201625301A (zh) 藉由ｆｏｌｒ１標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥
CA3209364A1 (en) Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
US20250243283A1 (en) Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
EA043382B1 (ru) Активируемые антитела против ctla-4 и их применение
CN116963745A (zh) 抗体的新型组合及其用途
HK1258304B (en) Optimized anti-cd3 bispecific antibodies and uses thereof
EA040594B1 (ru) Оптимизированные биспецифические анти-cd3 антитела и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220309

R150 Certificate of patent or registration of utility model

Ref document number: 7039582

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250